Form 8-K - Current report:
SEC Accession No. 0000950170-24-081531
Filing Date
2024-07-03
Accepted
2024-07-03 16:16:18
Documents
12
Period of Report
2024-07-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tern-20240701.htm   iXBRL 8-K 47934
2 EX-10.1 tern-ex10_1.htm EX-10.1 78496
  Complete submission text file 0000950170-24-081531.txt   260528

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tern-20240701.xsd EX-101.SCH 26982
14 EXTRACTED XBRL INSTANCE DOCUMENT tern-20240701_htm.xml XML 5119
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Filer) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39926 | Film No.: 241100331
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)